PPT-Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular

NICE CG 181 Continuum of CVD Risk and its treatment Post MIAngina Other Atherosclerotic Manifestations Subclinical Atherosclerosis Type 2 diabetes Multiple RFs QRISKgt10 Low Risk Secondary. Raymond Flood. Gresham Professor of Geometry. Joseph Fourier (1768–1830). Fourier’s life. Heat Conduction. Fourier’s series. Tide prediction. Magnetic compass. Transatlantic cable. Conclusion. Overview. S. tudies of . P. CSK9 . I. nhibition and . the . R. eduction of Vascular . E. vents) N = 31,887. SPIRE HR (n = 711). On maximally . tolerated statin. High risk of CV event. LDL-C ≥70 mg/dL. SPIRE LDL (n = . Ruff . et al. ., The Lancet, 2013. Ruff . et al. ., The Lancet, 2013. Secundary efficacy and safety outcomes in large NOAC trials, . vs. warfarin. Ruff . et al. ., The Lancet, 2013. Major bleeding events in large NOAC trials, vs warfarin. OU. tcomes. . R. esearch with PCSK9 . I. nhibition in subjects with . E. levated . R. isk. MS Sabatine, RP Giugliano, AC Keech, N Honarpour,. SM Wasserman, PS Sever, and TR Pedersen,. for the FOURIER Steering Committee & Investigators. CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. Evolocumab. in. Reducing Lipids and Cardiovascular . Events. Sabatine . MS. , . Giugliano RP. , . Wiviott . SD. ,. . e. t al. Kendrick Sparks, PGY3. September 17, 2015. Background. Reduction in LDL cholesterol has proven highly effective. 2013 ACC/AHA Guideline on the. Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. IMPROVE-IT. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia. Antidiabetes. Medications:. Cardiovascular Benefits. Hengameh. . Abdi. Endocrine Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 13 December 2018. Brian A. . Ference. MD, . MPhil. , . MSc. , John J. P. Kastelein MD, PhD, . Kausik. K. Ray MD, . MPhil. , Henry N. Ginsberg MD, M. John Chapman PhD, . DSc. , Chris J. Packard . DSc. , Ulrich . Laufs. Evidence from . meta-analyses of . Mendelian. . randomization. studies. , . prospective. cohort studies. , . and. . randomized. . controlled. trials . unequivocally establishes that LDL causes ASCVD. Acalabrutinib. Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL). Jennifer R. Brown,. 1 . John C. Byrd,. 2. Paolo Ghia,. 3. Jeff P. Sharman,. 4 . Peter Hillmen,. 5 . Deborah M. Stephens,. Page 1 of 20 UnitedHealthcare Commercial Medical Policy Effective 0 6 / 01 / 2022 Proprietary Information of UnitedHealthcare. Copyright 202 2 United HealthCare Services, Inc. UnitedHealthcareComme Darren K. McGuire, MD, . MHSc. Professor of Medicine. University of Texas Southwestern Medical Center. Conflict of Interest Disclosure. Clinical Trials Leadership. Takeda. Merck. Astra Zeneca. Janssen. Metabolics. , AstraZeneca. FMS Dec 2, 2013. Some examples from clinical development. Overview . Is inhibition of . cholesteryl. ester transfer protein (CETP) causing an increased risk for . CardioVascular.